BlueWind Medical receives CE Marking for its miniature implanted wireless stimulator to treat PNP
The BlueWind VIVENDI System is a wireless, battery-less neurostimulator which is 90% smaller than typical neurostimulators in the market.
BlueWind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, has received CE Marking for the BlueWind's VIVENDI miniature wireless neurostimulator to treat peripheral neuropathic pain (PNP). This is the second product BlueWind has received CE Marking based on its advanced neurostimulation platform, after obtaining few months ago CE Marking for treatment of an over active bladder.
An estimated 8 million people in Europe and 6 million in the US, suffer from PNP, including about 14% of all people with diabetes. PNP is a debilitating pain that impairs patient's quality of life, daily functioning, sleeps, work productivity and more. The most common treatment for PNP is pharmacological, including intensive use of Opioids, and PNP is one of the key contributors to the Opioid epidemic in the US.
The BlueWind VIVENDI System is a wireless, battery-less neurostimulator which is 90% smaller than typical neurostimulators in the market. The miniature device is implanted in close proximity to the Tibial nerve and by applying electrical stimulation to the nerve, helps to ease or mask the pain sensation. The device is implanted in a minimally invasive simple procedure lasting only about 30 minutes, and is powered wirelessly by an external control unit, conveniently worn on the ankle, as needed by the patient.
Patients self-administer the treatment using the wearable device as often and for as long as they need, and up to 8 hours a day. The reduction in pain is typically immediate and lasts between 30 minutes to a few hours post stimulation. In a multicentre clinical study performed in leading pain centres in Europe with 13 implanted patients, 83% of patients have reported more than 50% reduction in VAS pain scores over 6-month follow-up period.
"This new treatment paradigm, transforms the way patients are treated today, relieves them from the need for Opioid or other pharmacological treatments and allows them to control their own healing process," said Guri Oron BlueWind's CEO. "Until today, it was not possible to locally treat chronic peripheral pain with neurostimulators due to the size and complexity of existing neurostimulators. BlueWind's miniature and wireless neurostimulators are significantly smaller, allow for a simple implant procedure, precise targeting of the pain location, and are easier for patients to use at home."
"The BlueWind Vivendi system provides a solution to many patients that have no other relief," said Prof. Jean-Pierre Van Buyten, Chairman of the Multidisciplinary Pain Centre AZ Nikolaas in Belgium. "The small implant was very easy to implant, and very easy for the patients to activate and use. Patients can use it whenever they have pain and it provides immediate and sustainable pain relief."
"BlueWind VIVNEDI is our second product approved this year and it shows the power of the platform to expand to multiple indications and separate markets," said Efi Cohen Arazi, CEO of Rainbow Medical and Chairman of the Board of BlueWind Medical. "The company now have regulatory approval for two products and will continue to invest to further extend the usage of its platform."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance